Chimeric Therapeutics accelerates development of CAR T therapy as it looks to boost pipeline with additional therapies
- Chimeric Therapeutics granted European patent for cancer-fighting asset CHM 1101
- Chimeric Therapeutics licenses novel CAR T cell therapy with “transformative potential” from the University of Pennsylvania
- Chimeric Therapeutics with Proactive at the ASX Small and Mid Cap Conference
Quick facts: Chimeric Therapeutics Ltd
Price: 0.335 AUD
Market Cap: $111.7 m
About the company
Chimeric Therapeutics Ltd (ASX:CHM) is a clinical-stage company with a focus on research related to the usage of cell therapy for the treatment of cancer.
The company is developing CAR T cell therapies for solid tumours based on scientific research conducted by the US CAR T experts at the City of Hope Cancer Centre in Los Angeles.
Chimeric’s CLTX-CAR T technology incorporates chlorotoxin, a peptide derived from scorpion toxin, as a novel CAR tumour recognition domain.
How it is doing
The patent covers certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including CHM 1101, with patent protection expected until 2036.
This patent, granted by the European Patent Office under the technical name of EP 3,362,470 B1, means Chimeric holds the exclusive worldwide licence to develop and commercialise CHM 1101.
The news has brought a positive response from investors with shares up as much as 12.7% to A$0.355.
This Scientific Advisory Board has been established to provide expert guidance on the development of Chimeric’s growing pipeline of cellular immunotherapies.
Chimeric Therapeutics Ltd (ASX:CHM) has signed a strategic partnership deal with OncoBay Clinical to provide comprehensive research support to advance and expand the clinical development program for CHM 1101 (CLTX CAR T).
CHM 1101, a novel CAR T cell therapy that uniquely utilizes Chlorotoxin as its tumour targeting domain, has shown promising preclinical safety and efficacy and is being studied in a single site phase-I clinical trial.
Insight: Chimeric Therapeutics licenses novel CAR T cell therapy with “transformative...
Chimeric Therapeutics Ltd has licensed a novel cancer therapy for solid tumours from a world-renowned cell therapy centre.
Through an agreement with the University of Pennsylvania, the ASX-listed biotech will exclusively develop and commercialise the CDH17 chimeric antigen receptor T cell (CAR T) therapy.
What management says
Chimeric Therapeutics Ltd (ASX:CHM)'s Jennifer Chow speaks to Proactive's Andrew Scott from the ASX Small and Mid Cap Conference - September 2021. Chimeric is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. Its lead program is CHM 1101, a novel CAR T therapy, for the treatment of patients with Glioblastoma.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE